Publication

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Raymond, E
; 
Dahan, L
; 
Raoul, J
; 
Bang, Y
; 
Borbath, I
; 
Lombard-Bohas, C
; 
Valle, Juan W
; 
Metrakos, P
; 
Smith, D
; 
Vinik, A
... show 10 more
Citations
Altmetric:
Abstract
The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.
Authors
Raymond, E
Dahan, L
Raoul, J
Bang, Y
Borbath, I
Lombard-Bohas, C
Valle, Juan W
Metrakos, P
Smith, D
Vinik, A
Chen, J
Hörsch, D
Hammel, P
Wiedenmann, B
Van Cutsem, E
Patyna, S
Lu, Dongr
Blanckmeister, C
Chao, R
Ruszniewski, P
Affiliation
Service Inter-Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, France.
Description
Date
2011-02-10
Publisher
Collections
All Christie Publications
Medical Oncology
Show all metadata
Keywords
Type
Article
Citation
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. 2011, 364 (6):501-13 N. Engl. J. Med.
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/201093
Embedded videos